Supportive Care Intervention for Prostate Cancer
(TOPCOP3 Trial)
Trial Summary
What is the purpose of this trial?
This trial focuses on frequent health assessments and monitoring for older men with prostate cancer to identify and manage health issues early, aiming to improve patient outcomes.
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop your current medications. However, it mentions that participants should be starting or have recently started a specific type of prostate cancer medication (ARAT).
What data supports the effectiveness of the drug Lynparza (olaparib) for prostate cancer?
Is the GA+M Intervention (Olaparib and Radium-223) safe for humans?
How is the GA+M, GA+RSM, and RSM drug different from other prostate cancer drugs?
The GA+M, GA+RSM, and RSM drug, known as Lynparza (also called AZD-2281, MK-7339, KU0059436), is unique because it is a PARP inhibitor, which works by blocking an enzyme used by cancer cells to repair their DNA, leading to cell death. This mechanism is different from traditional treatments like chemotherapy or hormone therapy, which target cancer cells in other ways.1011121314
Research Team
Shabbir M Alibhai, MD MSc
Principal Investigator
UHN - Princess Margaret Cancer Centre
Eligibility Criteria
This trial is for men aged 70 or older with metastatic prostate cancer who are starting ARAT treatment. They must be able to give written consent and have a working phone. It's not for those who can't speak English, have a life expectancy under 3 months, or major neuropsychiatric issues like severe depression or dementia.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either GA+M, RSM, both interventions, or control for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- GA+M Intervention (Behavioural Intervention)
- GA+RSM intervention (Behavioural Intervention)
- RSM intervention (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Dr. Brad Wouters
University Health Network, Toronto
Chief Medical Officer since 2020
MD from University of Toronto
Dr. Kevin Smith
University Health Network, Toronto
Chief Executive Officer since 2018
Professor at McMaster University and University of Toronto